Triggered release of ciprofloxacin from nanostructured agglomerated vesicles

International Journal of Nanomedicine

Volumn 2, Issue 3, 2007, Pages 407-418

  Bhavane, Rohan ^a   Karathanasis, Efstathios ^b   Annapragada, Ananth V ^a,c  

^a University of Texas School of Health Information Sciences at Houston   (United States)

^b University of Houston   (United States)

^c NONE   (United States)

Author keywords

Agglomerated Vesicle Technology; Ciprofloxacin; Controlled released; Liposome encapsulated ciprofloxacin; Nanoparticle; Pulmonary delivery; Triggered release

Indexed keywords

CIPROFLOXACIN; CYSTEINE; LIPOSOME; NANOPARTICLE;

AGGLOMERATED VESICLE; AGGLOMERATED VESICLE TECHNOLOGY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG INSTILLATION; DRUG RELEASE; DRUG STRUCTURE; ENCAPSULATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIPOSOMAL DELIVERY; LUNG INFECTION; MALE; MAXIMUM PLASMA CONCENTRATION; NANOTECHNOLOGY; NONHUMAN; RABBIT; RAT; WISTAR RAT;

ORYCTOLAGUS CUNICULUS;

EID: 70350753018     PISSN: 11769114     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Bhavane R, Karathanasis E, Annapragada AV. 2003. Agglomerated vesicle technology: a new class of particles for controlled and modulated pulmonary drug delivery. Journal of Controlled Release, 93:15-28.
2. Fenlon CH, Cynamon MH. 1986. Comparative in vitro activities of ciprofloxacin and other 4-quinolones against Mycobacterium tuberculosis and Mycobacterium intracellulare. Antimicrob Agents Chemother, 29:386-88.
3. Gay JD, De Young DR, Roberts GD. 1984. In vitro activities of norfloxacin and ciprofloxacin against Mycobacterium tuberculosis, M. avium complex, M. chelonei, M. fortuitum, and M. kansasii. Antimicrob Agents Chemother, 26:94-6.
4. Karathanasis E, Ayyagari A, Bhavane R, et al. 2005. Preparation of in vivo cleavable agglomerated liposomes suitable for modulated pulmonary drug delivery. Journal of Controlled Release, 103(1):159-75.
5. Karathanasis E, Bhavane R, Annapragada AV. 2006. Triggered Release of Inhaled Insulin from the Agglomerated Vesicles: Pharmacodynamic Studies in Rats. Journal of Controlled Release, 113(2):117-27.
6. Lasic DD, Ceh B, Stuart MCA, et al. 1995. Transmembrane gradient driven phase transitions within vesicles: lessons for drug delivery. Biochimica Biophysica Acta, 1239:145-56.
7. Matot I, Manevich Y, Al-Mehdi A, et al. 2003. Fluorescence imaging of lipid peroxidation in isolated rat lungs during nonhypoxic lung ischemia. Free Radical Biology & Medicine, 34(6):785-90.
8. Sanders CC, Sanders WE Jr, Goering RV. 1987. Overview of preclinical studies with ciprofloxacin. Am J Med, 82:2-11.
9. Webb MS, Boman NL, Wiseman DJ et al. 1998. Antibacterial efficacy against an in vivo Salmonella typhimurium infection model and pharmacokinetics of a liposomal Ciprofloxacin formulation. Antimicrobial Agents and Chemotherapy, 42(1):45-52.
10. Wong JP, Yang H, Blasetti KL, et al. 2003. Liposome delivery of ciprofloxacin against intracellular Francisella tularensis infection. J Controlled Release, 92:265-73.
11. Zalipsky S. 1993. Synthesis of an end-group functionalized polyethylene glycol-lipid conjugate for preparation of polymer-grafted liposomes. Bioconjugate Chem, 4(4):296-9.